Compare Summit Therapeutics Inc (SMMT) vs Wells Fargo & Co (WFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Summit Therapeutics Inc vs Wells Fargo & Co — how do they compare? Summit Therapeutics Inc trades at $15.1 (market cap $12.06B), while Wells Fargo & Co trades at $88.94 (market cap $264.66B). The key difference: Wells Fargo & Co is far larger — about 21.9× Summit Therapeutics Inc's market cap, and Wells Fargo & Co pays a 2.29% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| SMMT | WFC | |
|---|---|---|
Market Cap | $12.06B | $264.66B |
Sector | Health | Financials |
52-Week High | $26.98 | $96.40 |
52-Week Low | $12.55 | $73.42 |
Enterprise Value | $11.39B | — |
Dividend Yield | — | 2.29% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Summit Therapeutics (SMMT) trades at $15.10, up 1.55% with a bullish technical signal and strong analyst support. The company shows negative profitability metrics with ROE at -192.5% and net income of -$1.08B for 2025, but maintains positive cash flow through financing activities. Recent developments include FDA review of ivonescimab with a November 2026 decision date and expansion into bladder cancer trials, driving investor optimism despite ongoing losses.
The investment case hinges on ivonescimab's regulatory approval potential, with a consensus price target of $27.90 representing 85% upside. Key risks include cash burn concerns, fiduciary duty investigations, and clinical trial outcomes. While fundamentals remain weak, the stock offers high-risk, high-reward potential for speculative biotech investors betting on successful drug commercialization.
Wells Fargo (WFC) trades at $89.15, up 1.82% for the day, with a bullish technical signal from moving averages and a consensus analyst price target of $97.64. Recent earnings show a Q2 2026 beat but misses in prior quarters, while revenue and net income have grown steadily from 2022 to 2025. The company is expanding into digital services like tokenized deposits, announced in August 2026, to enhance corporate client offerings.
The stock presents a value opportunity with a P/E of 12.72 and strong profitability metrics, including a 25.97% net income margin. Risks include volatile cash flows, with operating cash flow negative in 2025, and competitive pressures in banking. Analyst sentiment is mixed but leans positive, with 45% buy ratings, supporting potential upside if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →About Wells Fargo & Co
Wells Fargo is one of the largest banks in the United States, with approximately $1.9 trillion in balance sheet assets. The company is split into four primary segments: consumer banking, commercial banking, corporate and investment banking, and wealth and investment management. It is almost entirely focused on the U.S.
Read more on WFC →
